Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030
Amyotrophic lateral sclerosis is the most common degenerative disease of the motor neuron system, enables destroy nerve cells and causes disability. Amyotrophic lateral sclerosis is known as Lou Gehrings disease. Amyotrophic lateral sclerosis often begins with muscle twitching and weakness in a limb, or slurred speech. Afterwards, may affects the control of the muscles involved in movement, speaking, eating and breathing. There is no cure for the disease and eventually disease is fatal. The disease is inherited in 5% to 10% of cases and rest is unknown etiology. Researchers are studying several possible causes including gene mutation, chemical imbalance, and protein mishandling and disorganized immune response.Amyotrophic lateral sclerosis is difficult to diagnose, because it mimics various neurological disease symptoms. Generally ALS diagnosed using electromyogram, nerve conduction study, MRI, spinal tap and muscle biopsy. Blood and urine test are performed to sort out the other possible signs and symptoms. Two FDA approved drugs are available in the market, namely Riluzole and endaravone. Various therapies are available to reduce the symptoms of the disease.
Key Developments:
Most of the pipeline drugs for treatment of amyotrophic lateral sclerosis pipeline are at preclinical stages. Companies with pipeline molecules mostly focused on neuroprotection, immunomodulation,andglutamate excitotoxicity blockers for the treatment of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugsdevelopment. This report studies the dynamics of the Amyotrophic Lateral SclerosisPipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
|
Report Benchmarks |
Details |
|
By Route of Administration |
|
|
By Trial Phase |
|
Download Free Sample Report
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1. Executive Summary
2. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Introduction
2.1. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Taxonomy
2.2. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Definitions
2.2.1. Route of Administration
2.2.2. Trial Phase
3. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
3.6. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Competition Landscape
3.7. Epidemiology
4. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis,2019 - 2023 and Forecast, 2018 2024
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market opportunity analysis
5. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1. Oral
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Parenteral
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Others
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Forecast, By Trial Phase,2019 - 2023 and Forecast, 2017 2024
6.1. Pre-clinical phase
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Phase-I
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Phase II
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Phase-III
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Region, 2018 2024
8. North America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment MarketAnalysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
8.1.1. Oral
8.1.2. Parenteral
8.1.3. Others
8.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Pre-clinical phase
8.2.2. Phase-I
8.2.3. Phase II
8.2.4. Phase-III
8.3. Country Analysis 2016 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country, 2018 2024
8.5. North America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends
9. Europe Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
9.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Oral
9.1.2. Parenteral
9.1.3. Others
9.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Pre-clinical phase
9.2.2. Phase-I
9.2.3. Phase II
9.2.4. Phase-III
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
9.4. Europe Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 2024
9.5. Europe Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends
10. Asia-Pacific Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
10.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Oral
10.1.2. Parenteral
10.1.3. Others
10.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Pre-clinical phase
10.2.2. Phase-I
10.2.3. Phase II
10.2.4. Phase-III
10.3. Country Analysis2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)Â Â Â Â Â Â Â
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 2024
10.5. Asia-Pacific Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends
11. Latin America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2012 - 2012 - 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
11.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Oral
11.1.2. Parenteral
11.1.3. Others
11.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Pre-clinical phase
11.2.2. Phase-I
11.2.3. Phase II
11.2.4. Phase-III
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
11.4. Latin America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 2024
11.5. Latin America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends
12. Middle East and Africa Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
12.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Oral
12.1.2. Parenteral
12.1.3. Others
12.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Pre-clinical phase
12.2.2. Phase-I
12.2.3. Phase II
12.2.4. Phase-III
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 2024
12.5. MEA Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Mallinckrodt Pharmaceuticals
13.2.2. ASTELLAS PHARMA INC. (JAPAN)
13.2.3. REVALESIO CORPORATION (U.S.)
13.2.4. Amylyx Pharmaceutical Corp. (U.S.)
13.2.5. Mitsubishi Tanabe Pharma Corporation (Japan)
13.2.6. AB Science (France)
13.2.7. H. Boehringer Sohn AG &Co. KG (Germany)
14. Research Methodology
15. Key Assumptions and Acronyms
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
